Need for additional augmentation prior to implant placement · Adults aged 18 years or older, in good general health (including well-controlled systemic disease), requiring extraction of one or more…
The review found no eligible studies for this question.
1 finding from 1 review
Outcome not reported
0 studies
No studies found
Any other adverse effects of the interventions, such as gingival disease and demineralisation · Young people aged 9 to 14 years diagnosed with one or both palatally displaced permanent maxillary canines (PDC)
The review found no eligible studies for this question.
1 finding from 1 review
Changes in vertical height of alveolar ridge (mm) · Adults aged 18 years or older, in good general health (including well-controlled systemic disease), requiring extraction of one or more…
It is very uncertain whether ARP with alloplast changes changes in vertical height of alveolar ridge (mm) compared with extraction alone (very low certainty).
1 finding from 1 review
Overall treatment time wearing orthodontic appliances · Young people aged 9 to 14 years diagnosed with one or both palatally displaced permanent maxillary canines (PDC)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Complications (e.g. discomfort, pain and swelling) · Adults aged 18 years or older, in good general health (including well-controlled systemic disease), requiring extraction of one or more…
1 finding from 1 review
Costs and cost‐effectiveness · Young people aged 9 to 14 years diagnosed with one or both palatally displaced permanent maxillary canines (PDC)
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants referred for surgical exposure of the PDC · Young people aged 9 to 14 years diagnosed with one or both palatally displaced permanent maxillary canines (PDC)
It is very uncertain whether extraction of the primary (baby) canine (single primary tooth… changes number of participants referred for surgical exposure of the PDC compared with no extraction (non-intervention control) (very low certainty).
1 finding from 1 review
Intervention not reported
Death at one year · adults with renal vasculitis
The intervention showed no clear difference in death at one year (low certainty).
1 finding from 1 review
Intervention not reported
Dialysis at one year · adults with renal vasculitis
The intervention may leads to lower dialysis at one year (low certainty).
1 finding from 1 review
Remission · adults with renal vasculitis for maintenance therapy
Antibiotics showed no clear difference in remission at one year compared with placebo (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) probably leads to higher adverse effects (number of participants who had at least one adverse… compared with placebo (3 tablets/4 times a day (moderate certainty).
1 finding from 1 review
VSC: third component · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
Chlorine dioxide mouthrinse (with tongue scraping) showed no clear difference in VSC: third component compared with chlorhexidine mouthwash (with tongue scraping); GRADE not reported.
1 finding from 1 review
Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus may leads to higher number with complete or partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Complete response · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus may leads to higher number with complete response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Primary outcome: partial clinical response · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus showed no clear difference in number with partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Number with treatment failure by one year · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus may leads to lower number with treatment failure by one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Frequent relapses · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus may leads to lower number with frequent relapses by one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Number with steroid resistance by one year · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus showed no clear difference in number with steroid resistance by one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV showed no clear difference in continuing remission at one year compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review